Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib, GS-9876 and GS-4059 in Adult Subjects With Active Sjogren's Syndrome

NCT03100942 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT03100942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03100942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib, GS-9876 and GS-4059 in Adult Subjects With Active Sjogren's Syndrome
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Completed
Start date
May 1, 2017
Completion date
October 2, 2019
Enrollment
152 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

sjogren's syndrome